Literature DB >> 26921336

Cyclin A1 and P450 Aromatase Promote Metastatic Homing and Growth of Stem-like Prostate Cancer Cells in the Bone Marrow.

Regina Miftakhova1, Andreas Hedblom2, Julius Semenas2, Brian Robinson3, Athanasios Simoulis4, Johan Malm2, Albert Rizvanov5, David M Heery6, Nigel P Mongan7, Norman J Maitland8, Cinzia Allegrucci7, Jenny L Persson9.   

Abstract

Bone metastasis is a leading cause of morbidity and mortality in prostate cancer. While cancer stem-like cells have been implicated as a cell of origin for prostate cancer metastasis, the pathways that enable metastatic development at distal sites remain largely unknown. In this study, we illuminate pathways relevant to bone metastasis in this disease. We observed that cyclin A1 (CCNA1) protein expression was relatively higher in prostate cancer metastatic lesions in lymph node, lung, and bone/bone marrow. In both primary and metastatic tissues, cyclin A1 expression was also correlated with aromatase (CYP19A1), a key enzyme that directly regulates the local balance of androgens to estrogens. Cyclin A1 overexpression in the stem-like ALDH(high) subpopulation of PC3M cells, one model of prostate cancer, enabled bone marrow integration and metastatic growth. Further, cells obtained from bone marrow metastatic lesions displayed self-renewal capability in colony-forming assays. In the bone marrow, cyclin A1 and aromatase enhanced local bone marrow-releasing factors, including androgen receptor, estrogen and matrix metalloproteinase MMP9 and promoted the metastatic growth of prostate cancer cells. Moreover, ALDH(high) tumor cells expressing elevated levels of aromatase stimulated tumor/host estrogen production and acquired a growth advantage in the presence of host bone marrow cells. Overall, these findings suggest that local production of steroids and MMPs in the bone marrow may provide a suitable microenvironment for ALDH(high) prostate cancer cells to establish metastatic growths, offering new approaches to therapeutically target bone metastases. Cancer Res; 76(8); 2453-64. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26921336     DOI: 10.1158/0008-5472.CAN-15-2340

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  22 in total

1.  Androgenic to oestrogenic switch in the human adult prostate gland is regulated by epigenetic silencing of steroid 5α-reductase 2.

Authors:  Zongwei Wang; Libing Hu; Keyan Salari; Seth K Bechis; Rongbin Ge; Shulin Wu; Cyrus Rassoulian; Jonathan Pham; Chin-Lee Wu; Shahin Tabatabaei; Douglas W Strand; Aria F Olumi
Journal:  J Pathol       Date:  2017-12       Impact factor: 7.996

Review 2.  Bone Marrow Microenvironment as a Regulator and Therapeutic Target for Prostate Cancer Bone Metastasis.

Authors:  Sun H Park; Evan T Keller; Yusuke Shiozawa
Journal:  Calcif Tissue Int       Date:  2017-11-01       Impact factor: 4.333

3.  A cis-eQTL genetic variant of the cancer-testis gene CCDC116 is associated with risk of multiple cancers.

Authors:  Na Qin; Cheng Wang; Qun Lu; Tongtong Huang; Meng Zhu; Lihua Wang; Fei Yu; Mingtao Huang; Yue Jiang; Juncheng Dai; Hongxia Ma; Guangfu Jin; Chen Wu; Dongxin Lin; Hongbing Shen; Zhibin Hu
Journal:  Hum Genet       Date:  2017-06-26       Impact factor: 4.132

Review 4.  Prostate cancer induced bone pain: pathobiology, current treatments and pain responses from recent clinical trials.

Authors:  A E Smith; A Muralidharan; M T Smith
Journal:  Discov Oncol       Date:  2022-10-18

Review 5.  Emerging Contributions of Cancer/Testis Antigens to Neoplastic Behaviors.

Authors:  Zane A Gibbs; Angelique W Whitehurst
Journal:  Trends Cancer       Date:  2018-09-20

6.  Prostate cancer promotes a vicious cycle of bone metastasis progression through inducing osteocytes to secrete GDF15 that stimulates prostate cancer growth and invasion.

Authors:  Wenchu Wang; Xin Yang; Jinlu Dai; Yi Lu; Jian Zhang; Evan T Keller
Journal:  Oncogene       Date:  2019-02-12       Impact factor: 8.756

7.  FcγRIIIa receptor interacts with androgen receptor and PIP5K1α to promote growth and metastasis of prostate cancer.

Authors:  Per Flodbring Larsson; Richard Karlsson; Martuza Sarwar; Regina Miftakhova; Tianyan Wang; Azharuddin Sajid Syed Khaja; Julius Semenas; Sa Chen; Andreas Hedblom; Amjad Ali; Kristina Ekström-Holka; Athanasios Simoulis; Anjani Kumar; Anette Gjörloff Wingren; Brian Robinson; Sun Nyunt Wai; Nigel P Mongan; David M Heery; Daniel Öhlund; Thomas Grundström; Niels Ødum; Jenny L Persson
Journal:  Mol Oncol       Date:  2022-01-23       Impact factor: 7.449

8.  MTA1 drives malignant progression and bone metastasis in prostate cancer.

Authors:  Avinash Kumar; Swati Dhar; Gisella Campanelli; Nasir A Butt; Jason M Schallheim; Christian R Gomez; Anait S Levenson
Journal:  Mol Oncol       Date:  2018-08-14       Impact factor: 6.603

Review 9.  Molecular determinants of prostate cancer metastasis.

Authors:  Kiera Rycaj; Dean G Tang
Journal:  Oncotarget       Date:  2017-09-19

10.  miR‑30c suppresses prostate cancer survival by targeting the ASF/SF2 splicing factor oncoprotein.

Authors:  Ya-Qiang Huang; Xiao-Hui Ling; Run-Qiang Yuan; Zhi-Yun Chen; Sheng-Bang Yang; Hong-Xing Huang; Wei-De Zhong; Shao-Peng Qiu
Journal:  Mol Med Rep       Date:  2017-07-04       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.